Strongbridge Biopharma plc.
SBBP
SBBP was delisted on the 5th of October, 2021.
71 hedge funds and large institutions have $95.3M invested in Strongbridge Biopharma plc. in 2020 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 38 increasing their positions, 11 reducing their positions, and 16 closing their positions.
245% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 11
160% more call options, than puts
Call options by funds: $65K | Put options by funds: $25K
16% more capital invested
Capital invested by funds: $82.3M → $95.3M (+$13M)
1.62% less ownership
Funds ownership: 59.87% → 58.25% (-1.6%)
8% less funds holding
Funds holding: 77 → 71 (-6)
38% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 16
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.49M |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$536K |
| 3 |
BlackRock
New York
|
+$485K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$410K |
| 5 |
Two Sigma Advisers
New York
|
+$386K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$2.31M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.22M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.39M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$840K |
| 5 |
DMK
David M. Knott
|
-$781K |
SBBP Hedge Fund Activity: Q4 2020 in Review
71 of the 5,677 institutional investors tracked by Wall St. Rank reported a position in Strongbridge Biopharma plc. (SBBP) for Q4 2020, worth a combined $95.3M — up 16% from $82.3M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of SBBP and 10 opened new positions — a net loss of 6 holders — while 11 trimmed existing stakes and 38 added.
The largest buyer was Renaissance Technologies, adding an estimated $1.49M. The largest seller was Granite Point Capital Management, exiting entirely with an estimated $2.31M sold.
- 71 institutional investors held Strongbridge Biopharma plc. (SBBP) as of Q4 2020, down from 77 in Q3 2020.
- Funds reported $95.3M of Strongbridge Biopharma plc. stock for Q4 2020, up 16% quarter-over-quarter.
- 10 funds opened new Strongbridge Biopharma plc. positions in Q4 2020 and 16 closed out, a net change of -6 holders.
- The largest Strongbridge Biopharma plc. buyer in Q4 2020 was Renaissance Technologies, an estimated $1.49M added.
- The largest Strongbridge Biopharma plc. seller in Q4 2020 was Granite Point Capital Management, an estimated $2.31M sold.
Based on aggregated 13F filings for Q4 2020.